Abstract

 CADTH recommends that Bijuva be reimbursed by public drug plans for the treatment of patients with moderate-to-severe vasomotor symptoms (VMS) associated with menopause if certain conditions are met.
 Bijuva should only be covered to treat patients who have moderate-to-severe VMS associated with menopause and have an intact uterus.
 Bijuva should be reimbursed in a similar way to Bijuva’s individual components and all other forms of oral hormone replacement therapy (HRT) and should only be reimbursed if the cost of Bijuva provides savings for the drug plans relative to the cost of treatment with estradiol and progesterone as individual components.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
